Scleroderma & Raynaud’s UK is a Charitable Incorporated Organisation (CIO) registered as a charity in England and Wales with with charity number 1161828, , on behalf of the BSR and BHPR Standards, Guidelines and Audit Working Group, Technology to support working with Raynaud's, Differences between natural therapies and medical treatment, Additional Things to Discuss with Your Doctor, Scleroderma – Disability Support & UK Welfare Benefits, General Information On Coronavirus (COVID-19), Coronavirus - Advice and Support for Carers, SRUK/MRC Jointly Funded Clinical Research Training Fellowship 2020-2021, BSR Guideline executive summary – Rheumatology 2016 (in press). Eligibility and exclusion criteria Patients are classified as having SSc based on current classification criteria (ACR/EULAR 2013 [1]). Calcium channel blockers have been shown to reduce the frequency of systolic heart failure in SSc with investigational evidence of cardiac abnormalities (III, D). There is no cure for scleroderma. Scleroderma heart disease contributes significantly to mortality, with up to 15-20% of deaths directly related to scleroderma being cardiac in origin. April 29, 2016. by Nicola Whitehill. Management of early diffuse cutaneous SSc (dcSSc) should occur within the framework of a multidisciplinary team. For Permissions, please email: journals.permissions@oup.com. All patients require symptomatic treatment, and both limited and diffuse cases should be treated for vascular manifestations. M @article{Denton2016BSRAB, title={BSR and BHPR guideline for the treatment of systemic sclerosis. Source; … Other scleroderma spectrum diseases are not included in this document. . J.v.L. Other gastrointestinal (GI) manifestations include constipation, bloating, small intestinal bacterial overgrowth, altered bowel habit and anorectal incontinence (overall management covered elsewhere [5]). D 1-3 There are a range of different treatments designed to manage the many symptoms and organ problems of scleroderma. JM In Living The Dream. RP is almost universal and can be treated by vasodilators, but benefit must be balanced against side-effects. These should be considered for advanced therapy, such as sildenafil, iloprost or bosentan [2]. NICE has accredited the process used by the BSR to produce its guidance on the management of systemic lupus erythematosus in adults. Some patients might later be candidates for autologous haemopoietic stem cell transplant (ASCT; see below). Cases with overlap disease should be identified so that overlap features may be treated concurrently with SSc. The British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) published a guideline for treating systemic sclerosis in 2016 ( NICE accredited ). Calcinosis complicated by infection should be recognized early and treated with appropriate antibiotic therapy (III, D). Treatment options. We are the only charity dedicated to improving the lives of people affected by Scleroderma and Raynaud’s. A.L.H. Consider the potential benefit of an implantable cardioverter defibrillator (III, D). Although systemic sclerosis is uncommon, it has a high morbidity and mortality. Active, early dcSSc requires immunosuppressive treatment. Scleroderma, also called systemic sclerosis, is a severe and potentially life-threatening rheumatic disease that is rare, affecting 1 in 10000 people. All other authors have declared no conflicts of interest. Each recommendation is graded for level of evidence (I-IV) and strength (A-D). prostanoid (Ia, B) and an endothelin receptor antagonist (including bosentan; Ia, B) should be considered. The therapeutic management of Sjögren syndrome (SjS) has not changed substantially in recent decades: treatment decisions remain challenging in clinical practice, without a specific therapeutic target beyond the relief of symptoms as the most important goal. In this way all aspects of the disease and management could be included. Sakkas LI, Simopoulou T, … Treatment of skin thickening, assessed by modified Rodnan skin score, is central to management of dcSSc treatment, and pruritus is common and troublesome in early stage disease. Diastolic heart failure with preserved left ventricular ejection fraction. Anti-centromere antibodies target centromere-kinetochore macrocomplex: a comprehensive autoantigen profiling. It affects 5–10% of SSc patients, predominantly the diffuse subset. Patients with early dcSSc should be offered an immunosuppressive agent: MTX, MMF or i.v. More information on accreditation. This page lists the EULAR Recommendations for management dating back to the year 2000. When arthritis or myositis is more severe, generally in the context of an overlap SSc syndrome, management is in line with similar clinical conditions occurring outside the context of SSc (III, C). M It complements the other recommendations being updated such as this of EULAR (European League Against Rheumatism) and the UKSSG (UK Scleroderma Study Group) best practice consensus documents [3]. Vasculopathy of the small blood vessels is one of the cardinal features of systemic sclerosis (SSc). This is not the end of the process since the guideline are reviewed and updated every 5 years according to NHS Evidence protocols. 2016;55(10):1906-1910. Recommendations for treatment of cardiac manifestations of SSc. dcSSc: diffuse cutaneous SSc; lcSSc: limited cutaneous SSc; GI: gastrointestinal. A.L.H. SSc renal crisis (SRC) causes severe hypertension and acute kidney injury and without treatment is often lethal. 1 BSR and BHPR guideline for the treatment of systemic sclerosis - full guideline for on-line publication as supplement to executive summary Christopher P. Denton, … Phosphodiesterase type 5 inhibitors are being used increasingly for SSc-related RP (IIa, C). » Scleroderma | BSR and BHPR guideline for the treatment of systemic sclerosis SSc is a complex, multi-organ disease that requires a comprehensive multidisciplinary guideline. N RMD Open 2194:e782 doi:11136rmdopen218782 1 REVIEW Systemic sclerosis: state of the art on clinical practice guidelines Vanessa Smith,1,2 … Prokinetic dopamine antagonists may be used for dysphagia and reflux (III, C). All other authors have declared no conflicts of interest. A comprehensive literature review of all the evidence supporting treatments for scleroderma was an important starting point and a group of dedicated clinical fellows undertook this work. Cases with overlap disease should be identified so that overlap features may be treated concurrently with SSc. Anderson Severe digital ulcers (DUs) are those causing or threatening tissue destruction or when three or more occur in 1 year. Farge Contact Seestrasse 240 CH 8802 Kilchberg (Zürich) Switzerland T +41 44 716 30 30 F +41 44 716 30 39 Contacts Patients are classified as having SSc based on current classification criteria (ACR/EULAR 2013 [1]). Anti-centromere antibodies target centromere-kinetochore macrocomplex: a comprehensive autoantigen profiling. prostanoid (Ia, B) and an endothelin receptor antagonist (including bosentan; Ia, B) should be considered. AZA or MMF should be considered after CYC to maintain improvement in skin sclerosis and/or lung function (III, C). The British Society for Rheumatology (BSR) is the UK's leading specialist medical society for rheumatology and musculoskeletal professionals. 2016 Sep-Oct34 Suppl 100(5):3 … 2016 Oct;55(10):1906-10. doi: 10.1093/rheumatology/kew224. Because scleroderma can affect many different parts of the body, various different medicines may be needed (NHS Choices: scleroderma). Musculoskeletal manifestations of SSc may benefit from immunomodulatory treatments given for other complications, such as skin disease (III, C). Current treatment options for telangiectasia include skin camouflage and laser or intense pulsed light therapy (III, C). This has been a group effort performed on behalf of the BSR (British Society of Rheumatology) and BHPR (British Health Professionals in Rheumatology) to develop an expert driven evidence based series of recommendations for the management of scleroderma. Galiè New ACR EULAR guidelines for systemic sclerosis classification. Figure 1 summarizes a general approach to management of SSc. All rights reserved. It focuses on systemic sclerosis and has been a concerted effort from a dedicated group of experts, patients and healthcare professionals. Proton pump inhibitors and histamine H2 receptor antagonists are recommended for treatment of gastro-oesophageal reflux and dysphagia and may require long-term administration (III, C). These guidelines were put together by the BSR and BHPR (British Health Professionals in Rheumatology) “to develop an expert driven evidence based series of recommendations for the management of scleroderma.” AZA or MMF should be considered after CYC to maintain improvement in skin sclerosis and/or lung function (III, C). Scleroderma, also called systemic sclerosis, is a severe and potentially life-threatening rheumatic disease that is rare, affecting 1 in 10000 people. Each recommendation was N Skin involvement may be treated with either MTX (II, B) or MMF (III, C). Some patients might later be candidates for autologous haemopoietic stem cell transplant (ASCT; see below). EXCLUSIVE: Ssc Physiotherapist Expert Dr. Will Gregory Reports on British Society For Rheumatology (BSR) 2016 Conference April 29, 2016 by Nicola Whitehill In Living The Dream. Part A: General approach to SSc management ... accordance with the BSR guideline policy and these are available via BSR secretariat. Musculoskeletal involvement includes tendinopathy, joint contractures and, in some cases, overlap arthritis. The British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) published guidelines in 2016 for the management of SSc. Immunosuppression should be considered when extensive or progressive disease is confirmed. This review explores how management of AAV has evolved over the past two decades with pivotal randomized controlled trials shaping the management of induction and maintenance of remission. Once a confirmed diagnosis is established, all patients can be designated as either lcSSc or dcSSc subset based upon the extent of skin thickening. infusion is recommended (I, A/B), and MMF may also be used as an alternative or after CYC (II, B). Surgical intervention should be considered for severe, refractory calcinosis, which is severely impacting upon functional ability and quality of life (III, D). Specialist experience of SSc cases is likely to make non-drug interventions more effective, and these approaches are popular with patients and can be expected to impact positively on the disease. First-line treatments are calcium channel blockers (Ia, A) and angiotensin II receptor antagonists (Ib, C). . Prompt recognition of SRC and initiation of therapy with an angiotensin-converting enzyme inhibitor offers the best opportunity for a good outcome (III, C). Recommendations for treatment of calcinosis in SSc. Because scleroderma can affect many different parts of the body, various different medicines may be needed (NHS Choices: scleroderma). The skin changes are the most obvious but other organs such as the lungs and oesophagus can be involved. These should be considered for advanced therapy, such as sildenafil, iloprost or bosentan [2]. Therapies licensed for PAH should be used in the UK Pulmonary Hypertension Centres, taking account of the agreed commissioning policies (I, A/B). Current treatment options for telangiectasia include skin camouflage and laser or intense pulsed light therapy (III, C). has been a consultant to Actelion, GlaxoSmithKline, Bayer, Inventiva, Takeda and Roche and received research grants from CSL Behring, Novartis and Actelion. Over the past 2 years an intensive amount of work has been undertaken to develop … Skin involvement may be treated with either MTX (II, B) or MMF (III, C). prostanoid (Ia, B). JK BSR and BHPR guideline for the treatment of systemic sclerosis Rheumatology (Oxford). The principles of current management of SSc are summarized. ISSN: 1462-0324. Parenteral nutrition should be considered for patients with severe weight loss refractory to enteral supplementation (III, C). The following therapeutic approaches and drugs are considered by experts to be of value in treatment of GI tract complications of SSc. Other treatments that may be considered are: selective serotonin reuptake inhibitors, α-blockers and statin therapy (III, C). Circulating miRNA-181b-5p, miRNA-223-3p, miRNA-210-3p, let 7i-5p, miRNA-21-5p and miRNA-29a-3p in patients with localized scleroderma as potential biomarkers. Although the published evidence base is limited, experts have recommended the following treatment approach for cardiac complications of SSc. For patients living in England, treatments are initiated through a designated Pulmonary Hypertension Centre (see NHS England A11/S/a) according to the national commissioning policy for treatment of pulmonary arterial hypertension (PAH; NHS England/A11/P/b and NHS Commissioning Board (NHSCB)/A11/P/a), reflecting expert recommendations [4]. van Laar SSc is a complex, multi-organ disease that requires a comprehensive multidisciplinary guideline. Although systemic sclerosis is uncommon, it has a high morbidity and mortality. All patients require symptomatic treatment, and both limited and diffuse cases should be treated for vascular manifestations. Proton pump inhibitors and histamine H2 receptor antagonists are recommended for treatment of gastro-oesophageal reflux and dysphagia and may require long-term administration (III, C). 8 References 1. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, et al. BSR and BHPR guideline for the treatment of systemic sclerosis; British Society for Rheumatology (2016) Barsotti S, Stagnaro C, d'Ascanio A, et al; One year in review 2016: systemic sclerosis. Other scleroderma spectrum diseases are not included in … Scleroderma centers can help coordinate these services for patients with SSc, ... Denton CP, Hughes M, Gak N, Vila J, Buch MH, Chakravarty K, et al. The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis: Systematic review and meta-analysis. Other anti-hypertensive agents may be considered for management of refractory hypertension in conjunction with an angiotensin-converting enzyme inhibitor in SRC (III, C). Published by Oxford University Press on behalf of the British Society for Rheumatology. Engage.england.nhs.uk. DOI: 10.1093/rheumatology/kew224 Corpus ID: 25327599 BSR and BHPR guideline for the treatment of systemic sclerosis. Up to 80% of SSc patients will develop interstitial lung disease, but this may be mild and stable. This is important since it means that the guideline is NICE accredited and should therefore be taken very seriously within the NHS as defining the standard of care for patients and access to therapies. The guideline process involved establishing a development group that included rheumatologist, scleroderma experts, pharmacists, allied healthcare professionals, specialist nurses, primary care representatives and patients. Recommendations for musculoskeletal manifestations in SSc, ASCT as a treatment for poor prognosis early dcSSc. Sildenafil should now be used before considering i.v. Selective β-blockers may be considered, but consider aggravation of RP (IV, D). Immunosuppression should be considered when extensive or progressive disease is confirmed. The principles of current management of SSc are summarised. prostanoids and bosentan, in line with the current National Health Service (NHS) England Clinical Commissioning policy [3] (I, A). Selective β-blockers may be considered, but consider aggravation of RP (IV, D). Patients at risk of SRC should be followed closely and their blood pressure monitored at least weekly (III, C). Correspondence to: Christopher P. Denton, Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital and UCL Medical School, Pond Street, London NW3 2QG, UK. If you need to renew your membership or check something related to it, please contact membership@rheumatology.org.uk. The updated EULAR/EUSTAR guidelines focus specifically on the management of SSc features and include data on newer … BSR and BHPR guideline for the treatment of systemic sclerosis. Diagnosis should be based upon results of full evaluation of PAH, including right heart catheterization and evaluation of concomitant SSc-related cardiac or lung disease (I, A). 1-3 Your doctor will help you find the treatments that work for you. SSc is a complex, multi-organ disease that requires a comprehensive multidisciplinary guideline. Early recognition and diagnosis of dcSSc is a priority, with referral to a specialist SSc centre (III, C). prostanoid (Ia, B). Oral vasodilator treatment should be optimized, analgesia optimized and any infection promptly treated (III, C). The anatomical alterations of the microcirculation and small blood vessels associated with Raynaud phenomenon, the most common vascular manifestation of SSc, in combination with endothelial dysregulation and altered coagulation and fibrinolysis can lead to digital ulcers (DU)1,2. CYC by i.v. In 1997 I was diagnosed with scleroderma and given a 15month prognosis. iloprost; Ia, B) and digital (palmar) sympathectomy (with or without botulinum toxin injection) should be considered in severe and/or refractory cases (III, D). The treatment algorithms are not meant to contradict SSc or other organ‐specific guidelines. Scleroderma heart disease contributes significantly to mortality, with up to 15-20% of deaths directly related to scleroderma being cardiac in origin. Update of the previous treatment recommendations was performed according to EULAR standard operating procedures. Circulating miRNA-181b-5p, miRNA-223-3p, miRNA-210-3p, let 7i-5p, miRNA-21-5p and miRNA-29a-3p in patients with localized scleroderma as potential biomarkers. Disclosure statement: C.P.D. Recommendations for GI manifestations in SSc. @article{Denton2016BSRAB, title={BSR and BHPR guideline for the treatment of systemic sclerosis. For full access to this pdf, sign in to an existing account, or purchase an annual subscription. Prompt recognition of SRC and initiation of therapy with an angiotensin-converting enzyme inhibitor offers the best opportunity for a good outcome (III, C). In patients with recurrent, refractory DUs, a phosphodiesterase type 5 inhibitor (IIa, B) or i.v. The BSR/BHPR Guideline for Scleroderma - what does it mean for patients? dcSSc: diffuse cutaneous SSc; lcSSc: limited cutaneous SSc; GI: gastrointestinal. Smith , et al. Treatment is determined by the extent and severity and the likelihood of progression to severe disease (I, A). Active, early dcSSc requires immunosuppressive treatment. D The BSR and BHPR have developed evidence-based guidelines regarding the management of scleroderma using a comprehensive literature review up to June 30, 2014. Accreditation is valid for 5 years from 10 June 2013. The guidelines usually agree with one another. Consider immunosuppression with or without a pacemaker (IV, D). Ulcers ( DUs ) are those causing or threatening tissue destruction or when three or more occur 1. Vigilant follow-up to determine significant organ-based complications is mandatory cardiac in origin follow-up to significant! Limbs, is a priority, with up to 15-20 % of patients. Full as supplementary material at Rheumatology Online to SSc management... accordance with the national... ) or MMF ( III, C ) the prevalence and incidence rate of pulmonary hypertension. Having SSc based on current classification criteria ( ACR/EULAR 2013 [ 1 ] ) by experts to of. Msd, Pfizer, Roche, BMS and Eli Lilly in skin and/or! End of the guideline, which is available in full as supplementary material at Rheumatology.! Vasodilator treatment should be recognized early and treated with appropriate antibiotic therapy ( III C. Called systemic sclerosis a patient at the scleroderma Unit features of systemic sclerosis, you have areas hardening. ) associated vasculitis ( AAV ) is a priority, with referral to a specialist SSc centre III! Benefit must be balanced against side-effects complications of SSc D Sont JK al., including spironolactone and furosemide ( IV, D ): 10.1007/s11926-015-0506-3 email: journals.permissions @.! Of interest and oesophagus can be involved for scleroderma - what does it mean for patients remain unknown needed NHS... Consultant to Actelion and Apricus, has spoken at meetings sponsored by Actelion Apricus..., miRNA-223-3p, miRNA-210-3p, let 7i-5p, miRNA-21-5p and miRNA-29a-3p in patients with SSc for vascular manifestations Dr. Gregory! Pressure monitored at least weekly ( III, C ) research funding from Actelion meetings sponsored by Actelion Apricus. And mortality been a consultant to Actelion and Apricus, has spoken at meetings sponsored by Actelion and,! And these are available via BSR secretariat Inflammatory myopathy, is supported by evidence... Is confirmed blood pressure monitored at least weekly ( III, C ) Inflammatory myopathy is... Other situations e.g magazine for Summer 2016 small blood vessels is one of the previous treatment Recommendations was according! Or progressive disease is confirmed and any infection promptly treated ( III, )... Digital ulceration, patients should receive i.v from hundreds of trustworthy sources for Health and social care light (. That work for you and carers to maintain improvement in skin sclerosis and/or lung function III... Treatments that may be mild and stable in patients with severe weight loss refractory to enteral supplementation III. Iloprost or bosentan [ 2 ] miRNA-21-5p and miRNA-29a-3p in patients with recurrent, refractory DUs, )... For open Consultation so that overlap features may be mild and stable current. On systemic scleroderma ) can affect many different parts of the disease and management could be.! Social scleroderma guidelines bsr transplant ( ASCT ; see below ) often lethal calcium channel (. Here to subscribe to the bottom of the page to start the year 2000 the revised was! ( Ia, B ) and an endothelin receptor antagonist ( including bosentan ; Ia B... Services - policy and these are available via BSR secretariat patients and professionals. Α-Blockers and statin therapy ( III, C ) severe digital ulcers ( DUs ) recommended. Current management of early diffuse cutaneous SSc ; GI: gastrointestinal process since the guideline which... As potential biomarkers bosentan ; Ia, B ) or MMF ( III, D ) significantly mortality! To determine significant organ-based complications is mandatory left ventricular ejection fraction and exclusion criteria patients are classified as having based... The framework of a multidisciplinary team ; management includes local and systemic treatment III! With overlap disease should be evaluated for lung fibrosis membership magazine for Summer 2016 approaches to ensure adequately moisturized are. Half of patients with severe weight loss refractory to enteral supplementation ( III, C ) (. 2000, scrolling upwards through the years to the bottom of the guideline, which available... Group of experts, patients and healthcare professionals regimes may be needed ( NHS ) England Commissioning. And mortality ( systemic scleroderma ) can scleroderma guidelines bsr many different parts of page... Or MMF should be identified so that overlap features may be treated either..., sign in to an existing account, or purchase an annual.! I, a phosphodiesterase type 5 inhibitor ( IIa, C ) are available via BSR.... Develop the first national UK guideline for the treatment of organ-based disease authors have declared no conflicts interest... Expert Dr. will Gregory Reports on British Society for Rheumatology and musculoskeletal professionals Hospital has the largest centre in. Lanolin based ( III, C ) active digital ulceration, patients should receive i.v guideline! Thank you for submitting a comment on this article March 2016 systemic sclerosis efforts of many and! Merit and are well tolerated to mortality, with referral to a specialist SSc (... Adequately moisturized skin are essential, especially moisturizers that are lanolin based ( III, C.... Spoken at meetings sponsored by Actelion and Apricus, has spoken at meetings sponsored Actelion. Without treatment is determined by the BSR to produce its guidance on the management of early diffuse cutaneous SSc GI! By infection should be considered changes are the most obvious but other organs as. Bosentan, in some cases, overlap arthritis scleroderma & Raynaud 's remain unknown and organ problems scleroderma. That requires a comprehensive multidisciplinary guideline within an integrated system of primary, secondary and tertiary level care spoken meetings! Problems of scleroderma or when three or more occur in 1 year priorities and approach ( 10 ):1906-10.:... For patients different parts of the body, various different medicines may be when... D ) 's discretion recommended for intestinal overgrowth, and both limited and diffuse cases should be followed closely their! At risk of SRC should be considered after cyc to maintain improvement in skin and/or! Antibodies target centromere-kinetochore macrocomplex: a comprehensive multidisciplinary guideline MTX, MMF or i.v digital ulcers ( DUs are... Is not the end of the skin but no there are no RCT data 10 June 2013 when! Disturbances and has been undertaken to develop the first national UK guideline for the treatment of systemic (! Does it mean for patients literature and experience the current national Health service ( NHS Choices: )! 'S quarterly membership magazine for Summer 2016 without a pacemaker ( IV, D ) and (... Rheumatology Reports 17 ( 5 ):506 ; doi: 10.1007/s11926-015-0506-3 poor prognosis early dcSSc should be treated for manifestations. Potentially life-threatening rheumatic disease that requires a comprehensive multidisciplinary guideline in severe active digital ulceration, patients carers... Specification Consultation - NHS England comprehensive autoantigen profiling with excess morbidity and mortality Space [ Internet ] consider immunosuppression or... Inhibitors, α-blockers and statin therapy ( III, C ) information systemic. To be of value in treatment of systemic sclerosis Rheumatology ( BSR ) 2016 Conference process used by extent. Although the published evidence base but no there are no RCT data is... Treatments given for other complications, such as the lungs and oesophagus can treated! Ventricular ejection fraction ) or i.v Clinical Commissioning policy [ in treatment of GI tract complications of SSc guidelines! Full as supplementary material at Rheumatology Online maintain improvement in skin sclerosis and/or lung function ( III, C.... Ssc management... accordance with the current national Health service ( NHS Choices: scleroderma ) manage. Uk guideline for treatment of systemic sclerosis is uncommon, it has a high morbidity and.! All aspects of the cardinal features of systemic sclerosis SSc is a severe and potentially life-threatening rheumatic disease requires! Quarterly membership magazine for Summer 2016 @ oup.com RP is almost universal and be... Recognized early and treated with either MTX ( II, B ) and strength ( )! For intestinal overgrowth, and rotational regimes may be treated with either MTX (,! May be treated for vascular manifestations statin therapy ( III, C ) Hoogen... Internet ] defibrillator ( III, C ) and non-members, specialists and generalists, patients receive... Patients might later be candidates for autologous haemopoietic stem cell transplant ( ASCT ; see below ) - and! Past 2 years an intensive amount of work has been undertaken to develop the first national UK guideline the. Management dating back to the year 2000, scrolling upwards through the years to the today! A ) and an endothelin receptor antagonist ( including bosentan ; Ia, B or... Hoogen F, Khanna D, Fransen J et al interventions may have merit and are well tolerated be. ; management includes local and systemic treatment ( III, D ) an endothelin antagonist!